| Brand Name: | Anspar |
| Generic: | Sparfloxacin |
| Weight: | 100 mg |
| Type: | Tablet |
| Therapeutic Class: | 4-Quinolone preparations |
| Manufacturer: | Unimed Unihealth MFG. Ltd. |
| Price: | 14.00 |
| Last Updated: | 2020-11-20 18:15:00 |
Anspar Tablet contains Sparfloxacin. Anspar uses:
Anspar Tablet is indicated for the treatment of the following infections due to susceptible microorganisms:
Anspar Tablet contains Sparfloxacin 100 mg. Anspar doses:
In patients with normal renal function the recommended daily dose is two tablets of Anspar Tablet 200 mg on first day as a loading dose, thereafter take one tablet of Anspar Tablet 200 mg every 24 hours for a total of 10 days of therapy.
The recommended daily dose of Anspar Tablet in patients with renal impairment (Creatinine clearance < 30 ml/min) is two tablets of 200 mg taken on the first day as a loading dose. Thereafter, should be taken one tablet of 200 mg every 48 hours for total of 9 days of therapy.
Anspar Tablet can be taken with or without food.
Most of the adverse events were mild to moderate in severity and transient in nature. The most frequently reported events among the Anspar Tablet treated patients with the recommended dosage are: diarrhea, nausea, headache, dyspepsia, dizziness, insomnia, abdominal pain and QTc interval prolongation.
Anspar Tablet is a synthetic, broad-spectrum antibacterial agent from the difluoroquinolone family. It has been reported to be more active in vitro than ciprofloxacin against some organisms, including staphylococci and Mycobacteria, and has a much longer plasma half-life (16 hours).
Anspar Tablet inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
It should be used with caution in renal diseases, gastric ulcers and with concomitant use of NSAIDs. In renal failure of third degree severity (creatinine clearance < 30 ml/min) dosage modification is recommended 400 mg on 1st day, 200 mg on 2nd and 3rd day followed by 200 mg every 48 hours. Because fluoroquinolones have been associated with tendon rupture, Anspar Tablet should be discontinued at the first sign of tendon pain. Exposure to UV radiation during treatment should be avoided.
On concomitant use with Quinidine, Sotalol, Erythromycin, Astemizole, Terfenadine, vinca alkaloids there is increased risk of arrhythmia. Salts, oxides and hydroxides of Magnesium, Aluminium and Calcium decrease absorption of Anspar Tablet.
There are no adequate and well controlled studies in pregnant women. Anspar Tablet should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Anspar Tablet is contraindicated for individuals with a history of hypersensifivity and in achilles tend in its following the use of fluoroquinolone and in pregnancy and lactation. Anspar Tablet is contraindicated in patients with known QTc prolongation or in patients being treated concomitantly with medications known to produce an increase in the QTc interval and/or torsade depointes.
Use in children: Safety and effectiveness have not been established in patients below the age of 18 years.
Store at temperature below 30° C.
Anspar Tablet price in Bangladesh 14.00